and diluted common share ($0.51) $0.41
========= =========
Weighted average common shares
outstanding - basic and diluted 50,902 49,160
========= =========
7/31/2024 7/31/2023
Selected balance sheet data: (unaudited) (unaudited)
----------------------------------- -------------- --------------
Cash and cash equivalents (includes
restricted cash of $1,000 at
7/31/23) $ 52,371 $ 83,373
Working capital 45,237 58,467
Stockholders' equity 56,112 78,462
Total assets 85,764 121,880
The following table presents a reconciliation of
reported net loss and basic and diluted net loss per
share to Adjusted net loss and Adjusted basic and
diluted net loss per share for the twelve months
ended July 31, 2024.
ENZO BIOCHEM, INC.
Non-GAAP Reconciliation Table
(Unaudited, in thousands, except per share data)
Twelve months ended
July 31,
-----------------------
2024
--------------
Reported GAAP loss $ (26,078)
Adjusted for:
Discrete legal matters 2,377
Fair value adjustment 1,095
Discrete separation expenses 1,742
Net loss from discontinued operations 16,261
Adjusted net loss $ (4,603)
=== ==============
Weighted Shares Outstanding:
Basic and diluted 50,902
Basic and diluted earnings per share:
Basic and diluted net loss per share GAAP ($0.51)
Basic and diluted net loss per share non-GAAP ($0.09)
The following table presents a reconciliation of
reported GAAP net loss for the twelve months
ended July 31, 2024 to EBITDA and Adjusted
EBITDA:
ENZO BIOCHEM, INC.
EBITDA & Adjusted EBITDA Reconciliation Table
(Unaudited, in thousands)
Twelve months ended
July 31,
-------------------------
2024
--------------
GAAP net loss $ (26,078)
Plus (minus):
Depreciation and amortization 1,272
Interest (income) expense, net (3,341)
Income tax benefit - discontinued operations (390)
EBITDA (28,537)
Adjusted for:
Discrete legal matters 2,377
Fair value adjustment 1,095
Discrete separation expenses 1,742
Net loss from discontinued operations before
income tax benefit 16,651
Foreign exchange loss 192
Adjusted EBITDA $ (6,480)
=== ==============
(END) Dow Jones Newswires
October 29, 2024 19:59 ET (23:59 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。